perimenostage

Last checked September 2026 against 14 sources · Editorial policy

Veozah (fezolinetant) for hot flashes

Veozah (fezolinetant) is a non-hormonal pill for moderate to severe hot flashes and night sweats due to menopause, approved by the FDA in 2023. It blocks the neurokinin 3 receptor in the brain's temperature control center. The dose is one 45 mg tablet a day. It reduced hot flashes more than placebo from week 4, but it carries a boxed warning for rare serious liver injury, so liver blood tests are required.

Veozah is a non-hormonal pill for hot flashes. Side effects and the liver warning, cost and the savings card, how well it works, and what people report to the FDA.

Veozah for hot flashes: expectation vs reality

What people often expect

“Veozah is a hormone-free cure that works as well as HRT with no real risks”

What the evidence shows

It helps, but less dramatically than the headlines suggest. In the two main trials, women started with an average of 10.4 and 11.8 moderate to severe hot flashes a day; at week 12, Veozah cut them by 6.4 and 7.5 a day, compared with 3.9 and 5.0 on placebo. Rare serious liver injury led the FDA to add a boxed warning in December 2024.

How Veozah (fezolinetant) works for hot flashes

How fezolinetant works

Fezolinetant blocks neurokinin B from binding to the neurokinin 3 receptor on KNDy neurons in the brain's thermoregulatory center. When estrogen falls at menopause, this signaling contributes to hot flashes. Because Veozah acts in the brain rather than replacing estrogen, it doesn't treat vaginal dryness or protect bone, but it's an option when hormones aren't suitable.

Learn more →

How well Veozah works

In the two 12-week trials of 1,022 women with at least 7 moderate to severe hot flashes a day, Veozah 45 mg reduced hot flash frequency and severity more than placebo at weeks 4 and 12. The reduction over placebo was 2.1 and 2.6 hot flashes a day at week 4, and 2.6 and 2.5 at week 12. The effect is modest compared with estrogen, which cuts hot flashes by about 75%.

Learn more →

Veozah and liver injury

In trials, liver enzymes rose to more than 3 times the upper limit of normal in 2.3% of women. After a postmarketing report of serious liver injury within 40 days of starting, with tiredness, nausea, itching, yellow eyes and skin, light stools and dark urine, the FDA added a boxed warning in December 2024. The case improved after stopping the medicine.

Liver blood tests on Veozah

You need liver blood tests before starting. Veozah shouldn't be started if liver enzymes or bilirubin are 2 or more times the upper limit of normal. Tests are then repeated monthly for the first 3 months, and at 6 and 9 months. If enzymes rise above 3 times normal, testing becomes more frequent. Stop immediately and call your prescriber if you notice signs of liver problems.

Who shouldn't take Veozah

The label says Veozah shouldn't be used by women with known cirrhosis, severe kidney impairment or end-stage kidney disease, or those taking CYP1A2 inhibitors, a group of medicines that raise fezolinetant levels. Tell your doctor about every medicine you take. It's also important to know that Veozah doesn't prevent pregnancy, so perimenopausal women need contraception. Your pharmacist can check new prescriptions against it.

Veozah side effects

The most common side effects, in at least 2% of women and more than on placebo, were abdominal pain, diarrhea, insomnia, back pain, hot flash and raised liver enzymes. Across three trials, endometrial biopsies found one case of hyperplasia and one of cancer, a rate of 1% or less in the 45 mg group. Across the three trials, 1,100 women received Veozah, including a 52-week safety trial.

Veozah vs Lynkuet (elinzanetant)

Lynkuet, approved in the US in 2025, is a second drug in the same family. It blocks both neurokinin 1 and 3 receptors and is taken as two 60 mg capsules at bedtime. It can cause sleepiness, needs liver tests before starting and at 3 months, and since August 2026 carries a seizure warning. Veozah is one tablet a day. There are no head-to-head trials, so the choice depends on side effects, interactions and cost.

Learn more →

Veozah cost and the savings card

Veozah is brand-only, with no generic. The cash price is around $577.86 for 30 tablets, a month's supply, depending on the pharmacy. With commercial insurance, the Veozah Savings Card can bring the first month to $0 and each refill to $30, up to $4,000 a year. It doesn't apply to Medicare or Medicaid; uninsured women can apply to the Astellas Patient Assistance Program.

Learn more →

Veozah after breast cancer

Veozah is non-hormonal, which makes it an option for women who can't take estrogen, including many breast cancer survivors. The North American Menopause Society lists fezolinetant among recommended non-hormonal treatments with good evidence. Discuss it with your oncology team, especially if you take other medicines, because of drug interactions.

Learn more →

How to take Veozah

Take one 45 mg tablet once a day, at about the same time each day, with or without food. Swallow it whole with liquid; don't cut, crush or chew it. If you miss a dose, take it as soon as you can unless your next dose is less than 12 hours away, then return to your usual schedule the next day. Smoking didn't meaningfully change fezolinetant levels.

Veozah by the numbers

From the studies on this page

  • of women in trials had liver enzymes above 3 times normal

    2.3%

45 mg

once a day is the Veozah dose

2.5 to 2.6

fewer moderate to severe hot flashes a day than placebo at week 12

5

liver blood tests in the first 9 months: at months 1, 2, 3, 6 and 9, plus one before starting

Trial results are averages from women with at least 7 moderate to severe hot flashes a day; the effect for any individual varies.

Veozah side effects people report to the FDA

Veozah (fezolinetant): 2,122 reports to the FDA, 428 serious · data through July 30, 2026

ReactionReportsShare
Didn't work250
11.8%
ALT (liver enzyme) increased192
9.0%
Liver enzymes increased191
9.0%
AST (liver enzyme) increased147
6.9%
Headache121
5.7%
Nausea102
4.8%
Hot flash100
4.7%
Insomnia88
4.1%
Diarrhea81
3.8%
Fatigue78
3.7%
  • Reports with any liver term: 607 of 2,122 (28.6%).
  • Before the December 2024 boxed warning, 10% to 23% of reports each quarter mentioned the liver. In the first two quarters of 2025 that jumped to 50% and 69%, then settled at 22% to 36%. A warning that adds monthly blood tests catches more raised enzymes and prompts more reporting, so the jump doesn't mean the drug became more toxic.
  • The single most common report is that Veozah didn't work. In trials, it beat placebo by about 2.5 hot flashes a day at week 12, so some women notice little change.
See the full data →

Veozah vs other hot flash treatments

  • Veozah (fezolinetant)

    Strong evidence

    Targets the brain signal behind hot flashes, one tablet a day, works from week 4. Needs liver monitoring for 9 months. A good option if you can't or won't take hormones and don't take CYP1A2 inhibitors.

  • Estrogen HRT

    Strong evidence

    More effective, cutting hot flash frequency by about 75%, and also treats vaginal dryness and protects bone. Not suitable after hormone-sensitive breast cancer or with some clot and liver conditions.

    Related guide →
  • Elinzanetant (Lynkuet)

    Strong evidence

    A second neurokinin blocker, taken at bedtime; can cause sleepiness. Also requires liver tests. Its main trials, OASIS 1 and 2, reduced hot flashes from week 4, similar in timing to Veozah.

    Related guide →
  • SSRIs, SNRIs and gabapentin

    Strong evidence

    Older non-hormonal options that cut hot flashes by about 40% to 65%, available as cheap generics, with no liver monitoring requirement. Paroxetine interacts with tamoxifen.

    Related guide →

When to call a doctor on Veozah

  • Urgent: Tiredness, nausea, itching, yellow skin or eyes, light stools or dark urine

    Stop Veozah immediately and contact your prescriber. These can be signs of liver injury.

  • Urgent: Pain in the right upper abdomen or swelling of the belly

    Stop Veozah and contact your prescriber promptly; these are also listed signs of liver problems.

  • Starting any new medicine while on Veozah

    Check with a pharmacist; CYP1A2 inhibitors must not be taken with it.

  • Any bleeding after menopause

    See a doctor; bleeding always needs checking, whatever treatment you're on.

    More →

Veozah for hot flashes: questions women ask

What is Veozah used for?

Treating moderate to severe hot flashes and night sweats caused by menopause. It's a non-hormonal pill that works on the brain's temperature control center. It doesn't treat vaginal dryness or protect bone.

How well does Veozah work for hot flashes?

In trials, it reduced moderate to severe hot flashes by about 2.5 more per day than placebo at 12 weeks, from an average starting point of 10.4 to 11.8 a day. The benefit appears by week 4. Estrogen is more effective, cutting hot flash frequency by about 75%.

Is Veozah safe for the liver?

Serious liver injury is rare but possible, which is why it has a boxed warning. You'll need liver blood tests before starting, monthly for 3 months, and at 6 and 9 months, and you should stop it immediately if you notice signs of liver problems.

How long does Veozah take to work?

In trials, it reduced hot flashes more than placebo by week 4, with further benefit at week 12. Give it about 12 weeks before deciding whether it works for you.

Can I take Veozah with HRT?

It was studied as an alternative to hormones: women who had used HRT stopped it and had a wash-out period before joining the trials. Most women take one or the other, so ask your doctor if you're considering combining them.

Can I take Veozah after breast cancer?

It's non-hormonal, so it's an option for many women who can't take estrogen. Discuss it with your oncology team and check for interactions with your other medicines.

What are the side effects of Veozah?

The most common were abdominal pain, diarrhea, trouble sleeping, back pain, hot flash and raised liver enzymes. Serious liver injury is rare. Stop it and call your prescriber if you notice unusual tiredness, nausea, itching, yellow skin or eyes, light stools or dark urine.

How much does Veozah cost?

Around $577.86 for 30 tablets, a month's supply, if you pay cash, depending on the pharmacy. There's no generic. With commercial insurance, the Veozah Savings Card can make the first month $0 and refills $30, up to $4,000 a year. Medicare and Medicaid plans can't use the card.

What do Veozah reviews say?

In 2,122 reports to the FDA, the most common complaint is that it didn't work (250 reports), followed by raised liver enzymes. In trials, it cut hot flashes by about 2.5 a day more than placebo, so results vary from woman to woman. In the same trials, it also made the remaining hot flashes milder.

What if I miss a dose of Veozah?

Take it as soon as you remember, unless your next dose is less than 12 hours away. In that case skip it and go back to your usual schedule the next day. Don't take two tablets to catch up.

Does Veozah cause weight gain or affect the uterus?

Weight gain wasn't among the common side effects listed in the trials. Veozah isn't a hormone, and across three trials endometrial biopsies found hyperplasia or cancer in 1% or less of women on the 45 mg dose. Any bleeding after menopause still needs checking.

Sources

  1. Prescribing information: Veozah (fezolinetant tablets). Astellas Pharma, 2026. DailyMed, US National Library of Medicine.
  2. US Food and Drug Administration. Drug safety communication: FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant). December 2024.
  3. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091-1102.
  4. Conklin M, Santoro N. Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause. Ther Adv Reprod Health. 2023;17:26334941231177611.
  5. Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. JAMA. 2023;329(5):405-420.
  6. NHS. About hormone replacement therapy (HRT).
  7. Prescribing information: Lynkuet (elinzanetant capsules). Bayer HealthCare, 2026. DailyMed, US National Library of Medicine.
  8. Drugs.com. Veozah prices, coupons, copay cards and patient assistance. Accessed October 2026.
  9. Astellas Pharma. VEOZAH savings and support. Accessed October 2026.
  10. The North American Menopause Society. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.
  11. Pinkerton JV, Simon JA, Joffe H, et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials. JAMA. 2024;332(16):1343-54.
  12. Prescribing information: Brisdelle (paroxetine 7.5 mg capsules). Legacy Pharma, 2025. DailyMed, US National Library of Medicine.
  13. NHS. Postmenopausal bleeding.
  14. US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS): reports for fezolinetant (Veozah), via openFDA. Data through July 30, 2026.

See our editorial policy.

Related guides

Doctor-ready summary

Your stage in 2 minutes.

You leave with a stage estimate and a one-page summary sized for a short appointment.

Begin 2-minute stage check

Private · No app download

Sample report

Stage estimateLate transition
Sleep driving burden · TSH worth ruling out